{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:25:07Z","timestamp":1783484707092,"version":"3.55.0"},"reference-count":156,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.ijantimicag.2020.106258","type":"journal-article","created":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T12:02:53Z","timestamp":1607688173000},"page":"106258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Pharmacotherapy for Bordetella pertussis infection. I. A synthesis of laboratory sciences"],"prefix":"10.1016","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2743-0556","authenticated-orcid":false,"given":"Nevio","family":"Cimolai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2020.106258_bib0001","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/5584_2019_402","article-title":"Molecular epidemiology of Bordetella pertussis","volume":"1183","author":"Barkoff","year":"2019","journal-title":"Adv Exp Biol Med"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0002","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.3389\/fimmu.2019.01344","article-title":"Pertussis prevention: reasons for resurgence, and differences in the current acellular pertussis vaccines","volume":"10","author":"Esposito","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0003","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/5584_2019_408","article-title":"Pertussis: identification, prevention and control","volume":"1183","author":"Stefanelli","year":"2019","journal-title":"Adv Exp Biol Med"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0004","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.3201\/eid2512.181836","article-title":"High prevalence of macrolide-resistant Bordetella pertussis and ptxP1 genotype, Mainland China, 2014\u20132016","volume":"25","author":"Li","year":"2019","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0005","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-3466","article-title":"Acellular pertussis vaccine effectiveness over time","volume":"144","author":"Zerbo","year":"2019","journal-title":"Pediatrics"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0006","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/cid\/ciz199","article-title":"National outbreak of pertussis in England, 2011\u20132012: a case\u2013control study comparing 3-component and 5-component acellular vaccines with whole-cell pertussis vaccines","volume":"70","author":"Carvalho","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0007","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/jpids\/piz005","article-title":"The 112-year odyssey of pertussis and pertussis vaccines\u2014mistakes made and implications for the future","volume":"8","author":"Cherry","year":"2019","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0008","first-page":"663","article-title":"Management of whooping cough with special reference to infants","volume":"73","author":"Kohn","year":"1947","journal-title":"Am J Dis Child"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0009","first-page":"213","article-title":"Pertussis in infancy: a review of 3.018 cases","volume":"67","author":"Hoyne","year":"1950","journal-title":"Arch Pediatr"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0010","first-page":"537","article-title":"Treatment of whooping cough","volume":"9","author":"Bradford","year":"1951","journal-title":"Postgrad Med"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0011","first-page":"397","article-title":"Recent contributions to the diagnosis and treatment of pertussis","volume":"49","author":"Bradford","year":"1949","journal-title":"N Y State J Med"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0012","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1128\/JCM.41.3.1167-1172.2003","article-title":"Identification of a mutation associated with erythromycin resistance in Bordetella pertussis: implications for surveillance of antimicrobial resistance","volume":"41","author":"Bartkus","year":"2003","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0013","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1128\/JCM.01499-15","article-title":"Direct detection of erythromycin-resistant Bordetella pertussis in clinical specimens by PCR","volume":"53","author":"Wang","year":"2015","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0014","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/00006454-198601000-00051","article-title":"Erythromycin for treatment and prevention of pertussis","volume":"5","author":"Bass","year":"1986","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0015","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1517\/14656566.2.8.1275","article-title":"Current pharmacotherapy of pertussis","volume":"2","author":"Kerr","year":"2001","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0016","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/00016488409124962","article-title":"Whooping cough\u2014aspects of pathogenesis and treatment","volume":"407","author":"Trollfors","year":"1984","journal-title":"Acta Otolaryngol Suppl"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0017","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/BF01690992","article-title":"Comparison of media for agar dilution susceptibility testing of Bordetella pertussis and Bordetella parapertussis","volume":"14","author":"Hoppe","year":"1995","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"5 Suppl","key":"10.1016\/j.ijantimicag.2020.106258_bib0018","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1097\/01.inf.0000160916.47479.22","article-title":"Use of antibiotics in the prevention and treatment of pertussis","volume":"24","author":"Wirsing von K\u00f6nig","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0019","first-page":"1","article-title":"Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis; 2005 CDC guidelines","volume":"54","author":"Tiwari","year":"2005","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0020","article-title":"Variation in Bordetella pertussis susceptibility to erythromycin and virulence-related genotype changes in China (1970\u20132014)","volume":"10","author":"Yang","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0021","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.1128\/AAC.01081-13","article-title":"Appearance of macrolide-resistant Bordetella pertussis strains in China","volume":"57","author":"Wang","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0022","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/22221751.2019.1587315","article-title":"Genomic epidemiology of erythromycin-resistant Bordetella pertussis in China","volume":"8","author":"Xu","year":"2019","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0023","doi-asserted-by":"crossref","DOI":"10.1080\/14760584.2020.1831916","article-title":"The epidemic of erythromycin-resistant Bordetella pertussis with limited genome variation associated with pertussis resurgence in China","author":"Yao","year":"2020","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0024","article-title":"Effect of macrolides and \u03b2-lactams on clearance of Bordetella pertussis in the nasopharynx in children with whooping cough","author":"Mi","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0025","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1128\/AAC.00023-09","article-title":"Emergence of quinolone-resistant Bordetella pertussis in Japan","volume":"53","author":"Ohtsuka","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0026","series-title":"Manual of clinical microbiology","first-page":"838","article-title":"Bordetella and related genera","author":"Wirsing von K\u00f6nig","year":"2015"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0027","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/BF01644321","article-title":"Antimicrobial susceptibility of Bordetella pertussis (Part I)","volume":"16","author":"Hoppe","year":"1988","journal-title":"Infection"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0028","first-page":"807","article-title":"Erythromycin-resistant Bordetella pertussis\u2014Yuma County, Arizona, May\u2013October 1994","volume":"43","year":"1994","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0029","series-title":"Manual of clinical microbiology","article-title":"Bordetella","author":"Parker","year":"1980"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0030","series-title":"Laboratory diagnosis of bacterial infections","article-title":"Determination of antibacterial resistance","author":"Turnidge","year":"2001"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0031","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/jac\/28.5.621","article-title":"ARTs versus ASTs: where are we going?","volume":"28","author":"Sanders","year":"1991","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0032","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/jbmte.390010205","article-title":"Problems in large-scale culture of H. pertussis","volume":"1","author":"Billaudelle","year":"1959","journal-title":"J Biochem Microb Technol Eng"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0033","first-page":"520","article-title":"An improved liquid culture medium for the growth of Hemophilus pertussis","volume":"49","author":"Verwey","year":"1945","journal-title":"J Bacteriol"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0034","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1128\/jb.58.2.127-134.1949","article-title":"A simplified liquid culture medium for the growth of Hemophilus pertussis","volume":"58","author":"Verwey","year":"1949","journal-title":"J Bacteriol"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0035","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1128\/jb.50.6.651-654.1945","article-title":"The in vitro and in vivo activity of streptomycin against Hemophilus pertussis","volume":"50","author":"Hegarty","year":"1945","journal-title":"J Bacteriol"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0036","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0022-3476(49)80030-8","article-title":"Treatment of pertussis with polymyxin B (Aerosporin)","volume":"35","author":"Kaplan","year":"1949","journal-title":"J Pediatr"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0037","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1099\/00221287-63-2-211","article-title":"A simple chemically defined medium for production of Phase I Bordetella pertussis","volume":"63","author":"Stainer","year":"1971","journal-title":"J Gen Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0038","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/ajcp\/74.3.312","article-title":"Antibiotic susceptibility testing of Bordetella pertussis","volume":"74","author":"Field","year":"1980","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0039","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF01639525","article-title":"Comparison of erythromycin ethylsuccinate and co-trimoxazole for treatment of pertussis","volume":"17","author":"Hoppe","year":"1989","journal-title":"Infection"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0040","doi-asserted-by":"crossref","first-page":"878","DOI":"10.11150\/kansenshogakuzasshi1970.69.878","article-title":"Prevalence of pertussis in Fukuoka: incidence and MICs of antibiotics for Bordetella pertussis isolates","volume":"69","author":"Horikawa","year":"1995","journal-title":"Kansenshogaku Zasshi"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0041","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2105\/AJPH.36.4.371","article-title":"Pertussis vaccine prepared with Phase-I cultures grown in fluid medium","volume":"36","author":"Cohen","year":"1946","journal-title":"Am J Public Health Nations Health"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0042","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1007\/BF02013625","article-title":"Influence of culture medium and inoculum size on susceptibility of Bordetella pertussis to antibacterial agents in vitro","volume":"3","author":"Zackrisson","year":"1984","journal-title":"Eur J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0043","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1093\/jac\/15.5.629","article-title":"Susceptibility of Bordetella pertussis to doxycycline, cinoxacin, nalidixic acid, norfloxacin, imipenem, mecillinam and rifampicin","volume":"15","author":"Zackrisson","year":"1985","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0044","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/jac\/11.5.407","article-title":"In-vitro sensitivity of Bordetella pertussis","volume":"11","author":"Zackrisson","year":"1983","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0045","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1128\/AAC.34.7.1442","article-title":"In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to six new oral cephalosporins","volume":"34","author":"Hoppe","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0046","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1128\/AAC.34.11.2287","article-title":"In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to seven fluoroquinolones","volume":"34","author":"Hoppe","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0047","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/BF01968151","article-title":"Activity of new macrolides against Bordetella pertussis and Bordetella parapertussis","volume":"8","author":"Hoppe","year":"1989","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"Suppl B","key":"10.1016\/j.ijantimicag.2020.106258_bib0048","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/jac\/41.suppl_2.23","article-title":"The comparative in-vitro activity of roxithromycin and other antibiotics against Bordetella pertussis","volume":"41","author":"Brett","year":"1998","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0049","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1348-0421.1986.tb02975.x","article-title":"Serotype and drug susceptibility of Bordetella pertussis isolated in Japan from 1975 to 1984","volume":"30","author":"Watanabe","year":"1986","journal-title":"Microbiol Immunol"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0050","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0022-3476(96)70163-4","article-title":"Efficacy of short-term treatment of pertussis with clarithromycin and azithromycin","volume":"129","author":"Aoyama","year":"1996","journal-title":"J Pediatr"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0051","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1136\/jcp.21.2.202","article-title":"Trimethoprim: laboratory and clinical studies","volume":"21","author":"Darrell","year":"1968","journal-title":"J Clin Pathol"},{"issue":"Suppl 1","key":"10.1016\/j.ijantimicag.2020.106258_bib0052","doi-asserted-by":"crossref","first-page":"S264","DOI":"10.1007\/BF01645538","article-title":"In vitro activity and stability against novel \u03b2-lactamases of investigational \u03b2-lactams (cefepime, cefpirome, flomoxef, SCE 2787 and piperacillin plus tazobactam) in comparison with established compounds (cefotaxime, latamoxef and piperacillin)","volume":"19","author":"Bauernfeind","year":"1991","journal-title":"Infection"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0053","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jgar.2018.02.012","article-title":"Antimicrobial susceptibility testing of Finnish Bordetella pertussis isolates collected during 2006\u20132017","volume":"14","author":"L\u00f6nnqvist","year":"2018","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0054","first-page":"141","article-title":"Trimethoprim and sulphamethoxazole in whooping cough","volume":"14","author":"Mahadik","year":"1977","journal-title":"Indian Pediatr"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0055","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/BF01645369","article-title":"Antibacterial activity of cefpodoxime in comparison with cefixime, cefdinir, cefetamet, loracarbef, cefprozil, BAY 3522, cefuroxime, cefaclor and cefadroxil","volume":"19","author":"Bauernfeind","year":"1991","journal-title":"Infection"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0056","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/jac\/31.4.505","article-title":"Comparative in-vitro activities of the new quinolone, Bay Y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990","volume":"31","author":"Bauernfeind","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0057","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1749-6632.1950.tb42177.x","article-title":"Terramycin in pertussis: clinical and laboratory studies","volume":"53","author":"Jackson","year":"1950","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0058","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0022-3476(50)80230-5","article-title":"Antibiotic spectrum of Hemophilus pertussis","volume":"36","author":"Wells","year":"1950","journal-title":"J Pediatr"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0059","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0022-3476(66)80153-1","article-title":"Susceptibility of Bordetella pertussis to ampicillin","volume":"68","author":"Nelson","year":"1966","journal-title":"J Pediatr"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0060","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1128\/AAC.32.1.137","article-title":"Antimicrobial susceptibilities of Bordetella species isolate in a multicenter pertussis surveillance project","volume":"32","author":"Kurzynski","year":"1988","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0061","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1128\/JCM.38.3.1151-1155.2000","article-title":"A simplified method for testing Bordetella pertussis for resistance to erythromycin and other antimicrobial agents","volume":"38","author":"Hill","year":"2000","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0062","first-page":"84","article-title":"In vitro activity of \u03b2-lactam antibiotics against Bordetella pertussis: unusually high anti-B. pertussis activity of piperazine \u03b2-lactams","volume":"1","author":"Shishido","year":"1980","journal-title":"Curr Chemother Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0063","first-page":"1183","article-title":"Treatment of whooping cough and whooping cough syndrome by cefoperazone [in Japanese]","volume":"33","author":"Motohiro","year":"1980","journal-title":"Jpn J Antibiot"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0064","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1128\/AAC.32.11.1710","article-title":"Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides","volume":"32","author":"Hardy","year":"1988","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0065","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1046\/j.1469-0691.2000.00015-4.x","article-title":"In vitro activity of macrolides against Bordetella pertussis strains isolated in 1968 and 30 years later in Poland","volume":"6","author":"Chodorowska","year":"2000","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0066","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S0022-3476(69)80299-4","article-title":"Antimicrobial treatment of pertussis","volume":"75","author":"Bass","year":"1969","journal-title":"J Pediatr"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0067","first-page":"165","article-title":"Laboratory studies on ilotycin","volume":"3","author":"Powell","year":"1953","journal-title":"Antibiot Chemother (Northfield)"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0068","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1159\/000238503","article-title":"Susceptibility of Bordetella pertussis and Bordetella parapertussis to 24 antibiotics","volume":"33","author":"Hoppe","year":"1987","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0069","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0924-8579(97)00032-0","article-title":"Correlation of erythromycin agar dilution susceptibility testing with disc diffusion susceptibility for Bordetella pertussis","volume":"9","author":"Cimolai","year":"1997","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0070","first-page":"391","article-title":"Comparison of three media for agar dilution susceptibility testing of Bordetella pertussis using six antibiotics","volume":"17","author":"Hoppe","year":"1998","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0071","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1128\/jcm.35.11.2989-2991.1997","article-title":"Surveillance and detection of erythromycin resistance in Bordetella pertussis isolates recovered from a pediatric population in the Intermountain West region of the United States","volume":"35","author":"Korgenski","year":"1997","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0072","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000238545","article-title":"Bordetellae and charcoal horse blood agar: inactivation of antibiotics in agar during prolonged incubation for susceptibility testing","volume":"34","author":"Hoppe","year":"1988","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0073","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/BF02017801","article-title":"Comparison of three media for culture of Bordetella pertussis","volume":"5","author":"Hoppe","year":"1986","journal-title":"Eur J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0074","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1128\/JCM.40.8.2942-2944.2002","article-title":"Bordetella pertussis isolates with a heterogeneous phenotype for erythromycin resistance","volume":"40","author":"Wilson","year":"2002","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0075","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1128\/AAC.25.4.537","article-title":"Antibiotic resistance of degraded strains of Bordetella pertussis","volume":"25","author":"Bannatyne","year":"1984","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0076","doi-asserted-by":"crossref","first-page":"E260","DOI":"10.1111\/1469-0691.12161","article-title":"High-resolution melting analysis for the detection of two erythromycin-resistant Bordetella pertussis strains carried by healthy schoolchildren in China","volume":"19","author":"Zhang","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0077","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1099\/jmm.0.47602-0","article-title":"Co-infection with two different strains of Bordetella pertussis in an infant","volume":"57","author":"Cassiday","year":"2008","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0078","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s12519-019-00308-5","article-title":"Clinical characteristics, molecular epidemiology and antimicrobial susceptibility of pertussis among children in southern China","volume":"16","author":"Zhang","year":"2020","journal-title":"World J Pediatr"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0079","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/INF.0000000000002160","article-title":"Bordetella pertussis infection in infants and young children in Shanghai, China, 2016\u20132017: clinical features, genotype variations of antigenic genes and macrolides resistance","volume":"38","author":"Fu","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0080","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jgar.2019.01.029","volume":"18","author":"Hua","year":"2019","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0081","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1128\/jcm.27.9.2115-2117.1989","article-title":"Comparison of three kinds of blood and two incubation atmospheres for cultivation of Bordetella pertussis on charcoal agar","volume":"27","author":"Hoppe","year":"1989","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0082","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1128\/jcm.6.3.303-309.1977","article-title":"Enrichment medium for the isolation of Bordetella","volume":"6","author":"Regan","year":"1977","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0083","first-page":"276","article-title":"Susceptibility of Bordetella pertussis to nine antimicrobial agents","volume":"117","author":"Bass","year":"1969","journal-title":"Am J Dis Child"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0084","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1136\/jcp.25.8.732","article-title":"Selective medium for the isolation of Bordetella pertussis and parapertussis","volume":"25","author":"Sutcliffe","year":"1972","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0085","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/BF01644089","article-title":"Treatment and prevention of pertussis by antimicrobial agents (part II)","volume":"16","author":"Hoppe","year":"1988","journal-title":"Infection"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0086","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1128\/AAC.40.3.807","article-title":"In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to four fluoroquinolones (levofloxacin, d-ofloxacin, ofloxacin, and ciprofloxacin), cefpirome, and meropenem","volume":"40","author":"Hoppe","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0087","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1128\/AAC.42.4.965","article-title":"In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to two ketolides (HMR 3004 and HMR 3647), four macrolides (azithromycin, clarithromycin, erythromycin A, and roxithromycin), and two ansamycins (rifampin and rifapentine)","volume":"42","author":"Hoppe","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0088","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1128\/AAC.33.8.1144","article-title":"In vitro and in vivo activities of QA-241, a new tricyclic quinolone derivative","volume":"33","author":"Asahara","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0089","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1128\/AAC.45.12.3599-3600.2001","article-title":"Antimicrobial susceptibility testing of clinical isolates of Bordetella pertussis from northern California: report from the SENTRY Antimicrobial Surveillance Program","volume":"45","author":"Gordon","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0090","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ijantimicag.2006.11.024","article-title":"Antimicrobial susceptibility of Bordetella pertussis isolates in the state of Washington","volume":"29","author":"Galanakis","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0091","doi-asserted-by":"crossref","first-page":"e10880","DOI":"10.5812\/jjm.10880","article-title":"The first macrolide-resistant Bordetella pertussis strains isolated from Iranian patients","volume":"7","author":"Shahcheraghi","year":"2014","journal-title":"Jundishapur J Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0092","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/apm.12357","article-title":"Where macrolide resistance is prevalent","volume":"123","author":"Li","year":"2015","journal-title":"APMIS"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0093","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1099\/jmm.0.2008\/002857-0","article-title":"Antimicrobial susceptibility testing of Bordetella pertussis in Taiwan prompted by a case of pertussis in a paediatric patient","volume":"57","author":"Yao","year":"2008","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0094","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s10096-010-0976-1","article-title":"Antimicrobial susceptibility testing of historical and recent clinical isolates of Bordetella pertussis in the United Kingdom using the Etest method","volume":"29","author":"Fry","year":"2010","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0095","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/jac\/dkg145","article-title":"In vitro activity of fluoroquinolones against erythromycin-susceptible and erythromycin-resistant Bordetella pertussis","volume":"51","author":"Bourgeois","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0096","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1099\/jmm.0.000892","article-title":"Pertussis epidemiology in Tunisian infants and children and characterization of Bordetella pertussis isolates: results of a 9-year surveillance study, 2007 to 2016","volume":"68","author":"Ben Fraj","year":"2019","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0097","doi-asserted-by":"crossref","first-page":"7043","DOI":"10.1128\/AAC.01271-16","article-title":"In vitro activity of solithromycin against Bordetella pertussis, an emerging respiratory pathogen","volume":"60","author":"Hardy","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0098","first-page":"476","article-title":"S\u00e9rodiagnostic et variabilit\u00e9 des microbes suivant le milieu de culture [Serodiagnosis and variability of microbes depending on the culture medium","volume":"24","author":"Bordet","year":"1910","journal-title":"Ann Inst Pasteur"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0099","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1017\/S0022172400010950","article-title":"The phases of Haemophilus pertussis","volume":"31","author":"Leslie","year":"1931","journal-title":"J Hyg (Lond)"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0100","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1128\/iai.43.1.217-223.1984","article-title":"Isolation and characterization of Bordetella pertussis phenotype variants capable of growing on nutrient agar: comparison with phases III and IV","volume":"43","author":"Peppler","year":"1984","journal-title":"Infect Immun"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0101","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1128\/iai.43.1.263-269.1984","article-title":"Genetic analysis of phase change in Bordetella pertussis","volume":"43","author":"Weiss","year":"1984","journal-title":"Infect Immun"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0102","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/338266a0","article-title":"Phase variation in Bordetella pertussis by frameshift mutation in a gene for a novel two-component system","volume":"338","author":"Stibitz","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0103","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1172\/JCI102185","article-title":"Susceptibility of micro-organisms to chloramphenicol (Chloromycetin)","volume":"281","author":"McLean","year":"1949","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0104","first-page":"636","article-title":"Effects of spiramycin on experimental Hemophilus pertussis infection in mice [in French]","volume":"94","author":"Gastal","year":"1958","journal-title":"Ann Inst Pasteur (Paris)"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0105","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1128\/AAC.21.4.666","article-title":"Antimicrobial susceptibility of Bordetella pertussis strains isolated from 1960 to 1981","volume":"21","author":"Bannatyne","year":"1982","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0106","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1128\/AAC.26.4.604","article-title":"Susceptibility of Bordetella pertussis to cephalosporin derivatives and imipenem","volume":"26","author":"Bannatyne","year":"1984","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0107","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/BF01642314","article-title":"Effect of erythromycin and amoxicillin on Bordetella pertussis in the nasopharynx","volume":"6","author":"Trollfors","year":"1978","journal-title":"Infection"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0108","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/00006454-198705000-00009","article-title":"Erythromycin in the treatment of pertussis: a study of bacteriologic and clinical effects","volume":"6","author":"Bergquist","year":"1987","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0109","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1093\/jac\/dkm343","article-title":"Is Bordetella pertussis susceptibility to erythromycin changing? MIC trends among Australian isolates 1971\u20132006","volume":"60","author":"Sintchenko","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0110","doi-asserted-by":"crossref","first-page":"O825","DOI":"10.1111\/1469-0691.12671","article-title":"High prevalence of erythromycin-resistant Bordetella pertussis in Xi'an, China","volume":"20","author":"Wang","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0111","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1128\/AAC.42.7.1868","article-title":"In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to BAY 12-8039, trovafloxacin, and ciprofloxacin","volume":"42","author":"Hoppe","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0112","doi-asserted-by":"crossref","first-page":"282","DOI":"10.21101\/cejph.a4948","article-title":"Trends in the minimum inhibitory concentrations of erythromycin, clarithromycin, azithromycin, ciprofloxacin, and trimethoprim\/sulfamethoxazole for strains of Bordetella pertussis isolated in the Czech Republic, 1967\u20132015","volume":"25","author":"Jakubu","year":"2017","journal-title":"Cent Eur J Public Health"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0113","first-page":"208","article-title":"Antimicrobial susceptibility and antigen genotypes of Bordetella pertussis strains isolated from neonates","volume":"21","author":"Li","year":"2019","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0114","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0732-8893(87)90162-3","article-title":"Susceptibility of Bordetella pertussis to five quinolone antimicrobic drugs","volume":"8","author":"Appleman","year":"1987","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0115","first-page":"285","article-title":"Some laboratory and clinical observations on a new antibiotic, erythromycin (Ilotycin)","volume":"27","author":"Heilman","year":"1952","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0116","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3412\/jsb.30.487","article-title":"Properties of Bordetella pertussis recently isolated from infants [in Japanese]","volume":"30","author":"Cho","year":"1975","journal-title":"Nihon Saikingaku Zasshi"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0117","first-page":"865","article-title":"Treatment of pertussis with cefoperazone [in Japanese]","volume":"33","author":"Nakazawa","year":"1980","journal-title":"Jpn J Antibiot"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0118","first-page":"233","article-title":"Clinical results of latamoxef on pertussis [in Japanese]","volume":"36","author":"Minamitani","year":"1983","journal-title":"Jpn J Antibiot"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0119","first-page":"776","article-title":"Antimicrobial activities of clarithromycin against recent obtained clinical isolates [in Japanese]","volume":"50","author":"Suzuki","year":"1997","journal-title":"Jpn J Antibiot"},{"issue":"Suppl 1","key":"10.1016\/j.ijantimicag.2020.106258_bib0120","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/jac\/45.suppl_3.47","article-title":"In vitro activity of gemifloxacin and other antimicrobial agents against isolates of Bordetella pertussis and Bordetella parapertussis","volume":"45","author":"Mortensen","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0121","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jinf.2005.05.014","article-title":"In vitro activity of telithromycin against Gram-negative bacterial pathogens","volume":"52","author":"Felmingham","year":"2006","journal-title":"J Infect"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0122","doi-asserted-by":"crossref","first-page":"345","DOI":"10.7883\/yoken.67.345","article-title":"Clinical manifestations of children with microbiologically confirmed pertussis infection and antimicrobial susceptibility of isolated strains in a regional hospital in Japan, 2008\u20132012","volume":"67","author":"Horiba","year":"2014","journal-title":"Jpn J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0123","first-page":"81","article-title":"Surveillance of antimicrobial resistance in contemporary clinical isolates of Bordetella pertussis in Ontario","volume":"44","author":"Marchand-Austin","year":"2014","journal-title":"Canada. Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0124","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.mayocp.2014.08.004","article-title":"Pertussis outbreak, southern Minnesota, 2012","volume":"89","author":"Theofiles","year":"2014","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0125","first-page":"208","article-title":"Antimicrobial susceptibility and antigen genotypes of Bordetella pertussis strains isolated from neonates [in Chinese]","volume":"21","author":"Li","year":"2019","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0126","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3412\/jsb.30.501","article-title":"Drug sensitivity of recently isolated Bordetella pertussis and Bordetella parapertussis [in Japanese]","volume":"30","author":"Watanabe","year":"1975","journal-title":"Nihon Saikingaku Zasshi"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0127","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1128\/AAC.35.3.423","article-title":"Activity of temafloxacin against respiratory pathogens","volume":"35","author":"Swanson","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0128","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1128\/AAC.39.11.2544","article-title":"In vitro and in vivo antibacterial activities of S-1090, a new oral cephalosporin","volume":"39","author":"Tsuji","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0129","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1128\/AAC.41.11.2582","article-title":"In vitro and in vivo antibacterial activities of CS-940, a new fluoroquinolone, against isolates from patients with respiratory infections","volume":"41","author":"Miyazaki","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl Nov","key":"10.1016\/j.ijantimicag.2020.106258_bib0130","first-page":"10","article-title":"Combined antibacterial action in vitro of trimethoprim and sulphonamides: the in vitro nature of synergy","volume":"45","author":"Bushby","year":"1969","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0131","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/adc.47.252.311","article-title":"Trimethoprim\/sulphamethoxazole in pertussis: comparison with tetracycline","volume":"47","author":"Adcock","year":"1972","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0132","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1128\/jb.55.3.425-448.1948","article-title":"Chloromycetin: biological studies","volume":"55","author":"Smith","year":"1948","journal-title":"J Bacteriol"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0133","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1172\/JCI102170","article-title":"Comparison of the action of streptomycin, polymyxin B, aureomycin and chloromycetin on H. pertussis, H. parapertussis, H. influenzae and five enteric strains of Gram-negative bacilli","volume":"28","author":"Alexander","year":"1949","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0134","first-page":"257763","article-title":"Chloramphenicol in the treatment of pertussis: review of a hundred cases","author":"Lassen","year":"1951","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0135","first-page":"320","article-title":"Susceptibility of Hemophilus parapertussis to certain antibiotics","volume":"9","author":"Day","year":"1952","journal-title":"Pediatrics"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0136","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0022-3476(49)80005-9","article-title":"The action of aureomycin, of polymyxin B, and of streptomycin in experimental murine pertussis","volume":"35","author":"Bradford","year":"1949","journal-title":"J Pediatr"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0137","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1749-6632.1950.tb42162.x","article-title":"In vitro studies on terramycin","volume":"53","author":"Gocke","year":"1950","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0138","first-page":"121","article-title":"Laboratory and clinical studies with demeclocycline in pertussis","volume":"9","author":"Rama Rao","year":"1972","journal-title":"Indian Pediatr"},{"issue":"Suppl","key":"10.1016\/j.ijantimicag.2020.106258_bib0139","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1093\/infdis\/129.Supplement_2.S123","article-title":"Antimicrobial activity and human pharmacology of amoxicillin","volume":"129","author":"Neu","year":"1974","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0140","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1128\/AAC.42.1.94","article-title":"In vitro and in vivo antibacterial activities of S-4661, a new carbapenem","volume":"42","author":"Tsuji","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0141","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/BF01644322","article-title":"In vitro activity of flomoxef in comparison to other cephalosporins","volume":"16","author":"Simon","year":"1988","journal-title":"Infection"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0142","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1128\/AAC.35.8.1691","article-title":"In vitro antibacterial activity of ME1207, a new oral cephalosporin","volume":"35","author":"Miyazaki","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0143","doi-asserted-by":"crossref","first-page":"505","DOI":"10.7164\/antibiotics.45.505","article-title":"RU 29 246, the active compound of the cephalosporin-prodrug ester HR 916. I. Antibacterial activity in vitro","volume":"45","author":"Bauernfeind","year":"1992","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0144","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1080\/21645515.2016.1276139","article-title":"Severe pertussis infection in infants less than 6 months of age: clinical manifestations and molecular characterization","volume":"13","author":"Stefanelli","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0145","doi-asserted-by":"crossref","first-page":"e162","DOI":"10.1097\/INF.0000000000000262","article-title":"Occurrence of 3 Bordetella species during an outbreak of cough illness in Ohio: epidemiology, clinical features, laboratory findings and antimicrobial susceptibility","volume":"33","author":"Spicer","year":"2014","journal-title":"Pediatr Infect Dis J"},{"issue":"475","key":"10.1016\/j.ijantimicag.2020.106258_bib0146","first-page":"492","article-title":"Progressive respiratory distress in an infant treated for presumed pertussis","volume":"19","author":"Lee","year":"2000","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0147","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0140-6736(48)90090-7","article-title":"Chemotherapy and pharmacology of aerosporin: a selective Gram-negative antibiotic","volume":"1","author":"Brownlee","year":"1948","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0148","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/00006454-199505000-00010","article-title":"Pertussis caused by an erythromycin-resistant strain of Bordetella pertussis","volume":"14","author":"Lewis","year":"1995","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0149","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/INF.0000000000001366","article-title":"Antimicrobial susceptibility and molecular detection of pertactin-producing and pertactin-deficient Bordetella pertussis","volume":"36","author":"Souder","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0150","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0924-8579(96)00363-9","article-title":"Oxacillin susceptibility of coagulase-negative staphylococci: role for mecA genotyping and E-test susceptibility testing","volume":"8","author":"Cimolai","year":"1997","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0151","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1136\/adc.86.6.446","article-title":"Clinical validation for oxacillin susceptibility testing of coagulase negative staphylococci","volume":"86","author":"Cimolai","year":"2002","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0152","doi-asserted-by":"crossref","first-page":"966","DOI":"10.3201\/eid1806.120091","article-title":"Macrolide-resistant Bordetella pertussis infection in newborn girl","volume":"18","author":"Guillot","year":"2012","journal-title":"France. Emerg Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0153","doi-asserted-by":"crossref","first-page":"361","DOI":"10.7883\/yoken.JJID.2019.421","article-title":"The first report of macrolide-resistant Bordetella pertussis isolation in Japan","volume":"73","author":"Yamaguchi","year":"2020","journal-title":"Jpn J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0154","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.3201\/eid2610.201035","article-title":"Macrolide-resistant Bordetella pertussis, Vietnam, 2016\u20132017","volume":"26","author":"Kamachi","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0155","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1542\/peds.4.4.461","article-title":"Mechanism of emergence of resistance to streptomycin of H. pertussis and H. parapertussis during treatment with this antibiotic","volume":"4","author":"Alexander","year":"1949","journal-title":"Pediatrics"},{"key":"10.1016\/j.ijantimicag.2020.106258_bib0156","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0140-6736(50)90258-3","article-title":"Observations on chloramphenicol","volume":"255","author":"Gray","year":"1950","journal-title":"Lancet"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920304787?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920304787?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:42:21Z","timestamp":1760377341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857920304787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":156,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0924857920304787"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106258","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacotherapy for Bordetella pertussis infection. I. A synthesis of laboratory sciences","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106258","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106257","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106258"}}